Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
April 26, 2016 07:00 ET
|
Summit Therapeutics plc
Enrolment of Patients with DMD in the US Expected to Start 3Q 2016Utrophin Modulation Offers Differentiated Approach in DMD OXFORD, United Kingdom, April 26, 2016 (GLOBE NEWSWIRE) -- Summit...
Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
March 30, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...